A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-27. Anything still debated is marked as such rather than presented as settled.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Based on the data provided, the SCCS considers hydroxyapatite (nano) safe when used at concentrations up to 10% in toothpaste, and up to 0.465% in mouthwash. This safety evaluation only applies to the hydroxyapatite (nano) with the following characteristics: – composed of rod-shaped particles of which at least 95.8% (in particle number) have an aspect ratio of less than 3, and the remaining 4.2% have an aspect ratio not exceeding 4.9;
Narrated by Robin Ellis, produced by Rachel Allen, directed by Sarah Marris, made by TVF Media 24 May Storm in a D Cup, about breast implants; Sally Kirkland was a main protagonist against implants; Sybil Niden Goldrich of the Command Trust Network; Marcia Angell of The New England Journal of Medicine; the British 1990s glamour model Teresa May; Roger Sturrock of the University of Glasgow; Dennis Deapen of the University of Southern California; Sai Ramastry of the University of Illinois Chicago; British 1990s glamour model Hannah Callow sat nonchalantly on a London underground train, with surreptitious nearby male attention. Directed by Martin Durkin (often chose quite controversial topics), made by his company Kugelblitz 7 June Curse of the Phantom Limbs, about sensations of phantom limbs; Jackie Naylor lost her hand in an accident on the A57 in 1989; neuroscientist Peter Halligan, since 2018 the Chief Scientific Adviser for Wales; photographer Alexa Wright makes superfiction images of phantom limbs; the Douglas Bader Centre at the Queen Mary's Hospital, Roehampton; Canadian psychologist Ronald Melzack of McGill University; Conrad Weiskrantz, son of neuroscientist Lawrence Weiskrantz had a motorbike accident on a country road, where he hit a vehicle towing a trailer turning right; the Silver Spring monkeys; neuroscientist V. S. Ramachandran of University of California, San Diego; Canadian neurosurgeon Wilder Penfield conducted cortical stimulation mapping research in the 1950s, resulting in the cortical homunculus and cortical maps; neurosurgeon Tipu Aziz.
== Properties in protein structure == The distinctive cyclic structure of proline's side chain gives proline an exceptional conformational rigidity compared to other amino acids. It also affects the rate of peptide bond formation between proline and other amino acids. When proline is bound as an amide in a peptide bond, its nitrogen is not bound to any hydrogen, meaning it cannot act as a hydrogen bond donor, but can be a hydrogen bond acceptor. Peptide bond formation with incoming Pro-tRNAPro in the ribosome is considerably slower than with any other tRNAs, which is a general feature of N-alkylamino acids. Peptide bond formation is also slow between an incoming tRNA and a chain ending in proline; with the creation of proline-proline bonds slowest of all. The exceptional conformational rigidity of proline affects the secondary structure of proteins near a proline residue and may account for proline's higher prevalence in the proteins of thermophilic organisms. Protein secondary structure can be described in terms of the dihedral angles φ, ψ and ω of the protein backbone. The cyclic structure of proline's side chain locks the angle φ at approximately −65°. Proline acts as a structural disruptor in the middle of regular secondary structure elements such as alpha helices and beta sheets; however, proline is commonly found as the first residue of an alpha helix and also in the edge strands of beta sheets. Proline is also commonly found in turns (another kind of secondary structure), and aids in the formation of beta turns.
== History == Scurvy was known to Hippocrates, described in book two of his Prorrheticorum and in his Liber de internis affectionibus, and cited by James Lind. Symptoms of scurvy were also described by Pliny the Elder: (i) Pliny. "49". Naturalis historiae. Vol. 3.; and (ii) Strabo, in Geographicorum, book 16, cited in the 1881 International Encyclopedia of Surgery.
Sources: en.wikipedia.org
Polyadenylation is the covalent linkage of a polyadenylyl moiety to a messenger RNA molecule. In eukaryotic organisms most messenger RNA (mRNA) molecules are polyadenylated at the 3' end, but recent studies have shown that short stretches of uridine (oligouridylation) are also common. The poly(A) tail and the protein bound to it aid in protecting mRNA from degradation by exonucleases. Polyadenylation is also important for transcription termination, export of the mRNA from the nucleus, and translation. mRNA can also be polyadenylated in prokaryotic organisms, where poly(A) tails act to facilitate, rather than impede, exonucleolytic degradation. Polyadenylation occurs during and/or immediately after transcription of DNA into RNA. After transcription has been terminated, the mRNA chain is cleaved through the action of an endonuclease complex associated with RNA polymerase. After the mRNA has been cleaved, around 200–250 adenosine residues are added to the free 3' end at the cleavage site. This reaction is catalyzed by polyadenylate polymerase. Just as in alternative splicing, there can be more than one polyadenylation variant of an mRNA. Polyadenylation site mutations can occur. The primary RNA transcript of a gene is cleaved at the poly(A) addition site, and about 150–250 adenosines are added to the 3′ end of the RNA as a poly(A) tail. If this site is altered, cleavage and polyadenylation can shift to a downstream poly(A) site, producing an abnormally long and unstable mRNA.
Addiction is a neuropsychological disorder characterized by a persistent and intense urge to use a drug or engage in a behavior that produces an immediate psychological reward, despite substantial harm and other negative consequences. Repeated substance use produces long-lasting changes in brain networks involved in reward, executive function, stress reactivity and mood. These changes underlie both the intense drive to use a substance and the reduced capacity to control that urge. It is therefore understood as a brain disorder arising from a complex mix of psychosocial and neurobiological factors. A number of researchers argue that this framing is incomplete, and that addiction is better understood as learned behavior shaped by choice and social context. Addiction takes both substance and non-substance forms. Substance addictions include alcoholism, cannabis addiction, amphetamine addiction, cocaine addiction, nicotine addiction, and opioid addiction. The DSM-5-TR recognizes only gambling disorder as a behavioral (non-substance) addiction and lists internet gaming disorder as a condition for further study, while the ICD-11 additionally classifies gaming disorder as a disorder due to addictive behaviors. Other candidate behavioral addictions, and the question of whether food can be addictive, are debated in the research literature but are not recognized in either manual.
=== Clinical outcomes === In clinical trials the outcome of different types of treatment is compared to identify if a compound or regimen is favourable for the patient. The choice of treatment in the conditioning therapy can have a profound impact on progression-free survival (PNS), overall survival (OS), relapse incidence (RI) and non-relapse mortality (NRM). The studies mentioned summarize key findings comparing various conditioning regimens. Studies on conditioning regimens for hematopoietic cell transplant in primary central nervous system lymphoma (PCNSL) have shown that thiotepa based therapies thiotepa/busulfan/cyclophosphamide (TBC) and thiotepa/carmustine (TT-BCNU) improve progression-free survival of PCNSL compared to traditional therapies carmustine/etoposide/cytarabine/melphalan (BEAM). Research also suggests that in BEAM if carmustine is exchanged for thiotepa no statistical difference was found in PFS, OS and RI. Furthermore, the capacity of thiotepa to pass the blood-brain barrier may allow optimizing the therapy for patients with Central Nervous System involvement of increased CNS relapse risk. Another study compared total body irradiation (TBI) and thiotepa, busulfan and cyclophosphamide/fludarabine (TTB) as a conditioning regimen of patients with acute lymphoblastic leukemia undergoing allogenic hematopoietic stem cell transplantation. No statistical difference was found in the overall survival but the RI was higher in the TBI regimen but the NRM was lower with TTB suggesting that TBB might be a viable alternative to TBI.
Hegseth had announced on 10 October the formation of a new counternarcotics joint task force, to operate in Latin America, the Western hemisphere, and the area of the United States Southern Command (USSOUTHCOM), to be headed by the II Marine Expeditionary Force, intended "to crush the cartels, stop the poison and keep America safe". On 13 November 2025, Hegseth announced the unveiling of Operation Southern Spear, led by Joint Task Force Southern Spear and using a fleet with robotics and autonomous systems to target Latin American drug trafficking, with operations to begin later in November. A US official told a reporter in November that Hegseth's 13 November unveiling was "a formal operation naming for what the Joint Task Force Southern Spear ... and Southcom have already been doing in theater".
Cytometry by time of flight, or CyTOF, is an application of mass cytometry used to quantify labeled targets on the surface and interior of single cells. CyTOF allows the quantification of multiple cellular components simultaneously using an ICP-MS detector. CyTOF takes advantage of immunolabeling to quantify proteins, carbohydrates or lipids in a cell. Targets are selected to answer a specific research question and are labeled with lanthanide metal tagged antibodies. Labeled cells are nebulized and mixed with heated argon gas to dry the cell containing particles. The sample-gas mixture is focused and ignited with an argon plasma torch. This breaks the cells into their individual atoms and creates an ion cloud. Abundant low weight ions generated from environmental air and biological molecules are removed using a quadrupole mass analyzer. The remaining heavy ions from the antibody tags are quantified by Time-of-flight mass spectrometry. Ion abundances correlate with the amount of target per cell and can be used to infer cellular qualities. Mass spectrometry's sensitivity to detect different ions allows measurements of upwards of 50 targets per cell while avoiding issues with spectral overlap seen when using fluorescent probes. However, this sensitivity also means trace heavy metal contamination is a concern. Using large numbers of probes creates new problems in analyzing the high dimensional data generated.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.